[go: up one dir, main page]

HN2001000215A - Tecnica de transfeccion intensificada - Google Patents

Tecnica de transfeccion intensificada

Info

Publication number
HN2001000215A
HN2001000215A HN2001000215A HN2001000215A HN2001000215A HN 2001000215 A HN2001000215 A HN 2001000215A HN 2001000215 A HN2001000215 A HN 2001000215A HN 2001000215 A HN2001000215 A HN 2001000215A HN 2001000215 A HN2001000215 A HN 2001000215A
Authority
HN
Honduras
Prior art keywords
intensified
transfection technique
mammer
cells
protein
Prior art date
Application number
HN2001000215A
Other languages
English (en)
Inventor
Myung-Sam Cho
Helena Yee
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of HN2001000215A publication Critical patent/HN2001000215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE EN GENERAL A UNA MEJORA DE LOS SISTEMAS DE EXPRESION EN CELULAS DE MAMIFEROS Y SE RELACIONA EN ESPECIAL CON UN SISTEMA VECTOR DE EXPRESION GENICA EN CEELULAS DE MAMIFEROS QUE INCLUYE UN SISTEMA DE MANTENIMIENTO EPISOMAL, UN FUERTE PROMOTOR/INTENSIFICADOR, UN COMPLEJO DE TRANSACTIVACION DE PROTEINAS Y UN ADN QUE CODIFICA PARA UNA PROTEINA HETEROLOGA
HN2001000215A 2000-09-28 2001-09-25 Tecnica de transfeccion intensificada HN2001000215A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67584700A 2000-09-28 2000-09-28

Publications (1)

Publication Number Publication Date
HN2001000215A true HN2001000215A (es) 2003-11-11

Family

ID=24712193

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2001000215A HN2001000215A (es) 2000-09-28 2001-09-25 Tecnica de transfeccion intensificada

Country Status (18)

Country Link
EP (1) EP1356069B1 (es)
JP (1) JP5022555B2 (es)
AR (1) AR035495A1 (es)
AU (1) AU2001289075A1 (es)
CA (1) CA2420771C (es)
CO (1) CO5270027A1 (es)
DE (1) DE60119386T2 (es)
DO (1) DOP2001000254A (es)
EC (1) ECSP014147A (es)
ES (1) ES2263652T3 (es)
GT (1) GT200100194A (es)
HN (1) HN2001000215A (es)
MY (1) MY139948A (es)
PE (1) PE20030412A1 (es)
SV (1) SV2002000640A (es)
TW (1) TWI239354B (es)
UY (1) UY26947A1 (es)
WO (1) WO2002027005A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006121995A (ja) * 2004-10-29 2006-05-18 Tokyo Medical & Dental Univ Ｅｂｎａ１変異体
WO2007048601A1 (en) 2005-10-28 2007-05-03 F. Hoffmann-La Roche Ag Protein expression in rodent cells
EP2478107B1 (en) 2009-09-15 2018-08-29 Medimmune Limited Cells for transient expression and uses thereof
CN104995299B (zh) 2012-12-11 2020-02-28 宝生物工程株式会社 表达盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
US6150515A (en) * 1996-07-03 2000-11-21 Massachusetts Institute Of Technology Tat-SF: cofactor for stimulation of transcriptional elongation by HIV-1 Tat
US6465251B1 (en) * 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
DZ2788A1 (fr) * 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
IT1302403B1 (it) * 1998-11-06 2000-09-05 Angeletti P Ist Richerche Bio Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso.
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression

Also Published As

Publication number Publication date
EP1356069A2 (en) 2003-10-29
ECSP014147A (es) 2002-05-23
CA2420771C (en) 2010-12-21
DE60119386T2 (de) 2007-04-19
UY26947A1 (es) 2002-04-26
SV2002000640A (es) 2002-10-24
DOP2001000254A (es) 2002-06-15
TWI239354B (en) 2005-09-11
CA2420771A1 (en) 2002-04-04
CO5270027A1 (es) 2003-04-30
WO2002027005A3 (en) 2003-07-31
PE20030412A1 (es) 2003-06-26
WO2002027005A9 (en) 2003-02-06
ES2263652T3 (es) 2006-12-16
EP1356069B1 (en) 2006-05-03
DE60119386D1 (de) 2006-06-08
JP2004509642A (ja) 2004-04-02
MY139948A (en) 2009-11-30
WO2002027005A2 (en) 2002-04-04
AU2001289075A1 (en) 2002-04-08
AR035495A1 (es) 2004-06-02
JP5022555B2 (ja) 2012-09-12
GT200100194A (es) 2002-05-16

Similar Documents

Publication Publication Date Title
ES2169258T3 (es) Utilizacion de proteasa de subtilisina mutada en productos cosmeticos.
ES2114588T3 (es) Forma farmaceutica de un gel acuoso que contiene un retinoide.
ES2148345T3 (es) Composicion farmaceutica con ciclosporina a, un derivado de vitamina e y un emulsionante.
ES2192301T3 (es) Derivados de resorcinol.
DE69711045D1 (de) Vitamin c abgabesystem
ES2056817T5 (es) Transformacion de trichoderma.
ES2177673T3 (es) Uso de flavonoides como agentes inmunorreguladores o inmunoprotectoresen preparaciones cosmeticas y dermatologicas.
ES2147579T3 (es) Sistema de blanqueado de multiples componentes.
HN1998000115A (es) Formas de dosificación farmacéuticas sólidas
HN2002000153A (es) Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester.
PT873405E (pt) Elementos de sequencia que aumentam a expressao (ease) para sistemas de expressao eucarioticos
DE60038104D1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
ES2137251T3 (es) Sero-albumina humana, preparacion y utilizacion.
ES2189992T3 (es) Reduccion del crecimiento del pelo.
HN2001000006A (es) Antagonistas del factor liberador de corticotropina
HN2001000262A (es) Kit de repinotano
HN2001000215A (es) Tecnica de transfeccion intensificada
ES2186009T3 (es) Dendrimeros de epoxi-amina y la preparacion y uso de los mismos.
PT1131408E (pt) Acidos oligossacarido-aldonicos e sua utilizacao topica
ES2140175T3 (es) Utilizacion de la monoetanolamina para preparar una composicion destinada para determinar los cueros cabelludos sensibles.
CO5290297A1 (es) Factor activador de la citoquina altamente purificado y metodos de su uso
AR009819A1 (es) Inhibidores de la proteasa proteinicos estabilizados y sus variantes
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
DK0977871T3 (da) Neurotrypsin
ATE28188T1 (de) Antikonvulsive mittel.